Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders

September 24, 2018 updated by: Probi AB
To assess the effect of a probiotic product, when co-administered with antibiotics, on gastrointestinal symptoms following antibiotic treatment in children.

Study Overview

Study Type

Interventional

Enrollment (Actual)

117

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 11 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children at the age of 1-11 years that have been prescribed antibiotic treatment.
  • Problems with loose stools during earlier antibiotic treatments.
  • Children whose parents or legal caregivers have signed the informed consent to participate in the study.

Exclusion Criteria:

  • Chronic intestinal disease, immunodeficiency or immunosuppressive treatment.
  • Chronic or acute diarrheal disease.
  • Use of laxatives the week before inclusion in the study.
  • Antibiotic treatment for the last four weeks before inclusion in the study.
  • Intake of probiotic products for the last two weeks before inclusion in the study.
  • Known hypersensitivity to any of the ingredients in the probiotic product or the placebo (potato starch ± bacterial culture that may contain traces of soy).
  • Patient requiring hospitalisation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Active Comparator: Probiotics

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of loose/watery stools
Time Frame: 19-26 days
19-26 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Piotr Socha, Prof., Children's Memorial Health Institute, Warzaw, Poland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 3, 2016

Primary Completion (Actual)

May 8, 2017

Study Completion (Actual)

May 8, 2017

Study Registration Dates

First Submitted

March 16, 2016

First Submitted That Met QC Criteria

March 23, 2016

First Posted (Estimate)

March 30, 2016

Study Record Updates

Last Update Posted (Actual)

September 26, 2018

Last Update Submitted That Met QC Criteria

September 24, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ProGastro Kids 16

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antibiotic-associated Diarrhea

Clinical Trials on Placebo

3
Subscribe